<--- Back to Details
First PageDocument Content
Health / Artemisinin / The International Pharmacopoeia / Validation / Good manufacturing practice / Dihydroartemisinin / Counterfeit medications / Verification and validation / Artemisia annua / Pharmaceutical industry / Pharmaceutical sciences / Technology
Date: 2010-04-25 04:58:29
Health
Artemisinin
The International Pharmacopoeia
Validation
Good manufacturing practice
Dihydroartemisinin
Counterfeit medications
Verification and validation
Artemisia annua
Pharmaceutical industry
Pharmaceutical sciences
Technology

Microsoft Word - StartingMaterials-QAS10-349.doc

Add to Reading List

Source URL: www.cgalp.com

Download Document from Source Website

File Size: 299,13 KB

Share Document on Facebook

Similar Documents

Design for Test (DfT) Consultancy DfT Consulting Services Good practice in DfT during SoC design and verification can improve time to market and reduce manufacturing costs.

DocID: 1tBJF - View Document

Use of wooden shelves for cheese aging Microbial pathogens can be controlled if food facilities engage in good manufacturing practice. Proper cleaning and sanitation of equipment and facilities are absolutely necessary t

DocID: 1tjBZ - View Document

Health / Medicine / Pharmaceutical industry / Pharmaceuticals policy / Canadian law / Health in Canada / Natural health product / Homeopathy / Good manufacturing practice / Medsafe / Health freedom movement

15 FebruaryMinistry of Health PO Box 5013 Wellington 6145 By email:

DocID: 1rt2X - View Document

Evaluation / Pharmaceutical industry / Health / Quality / Pharmaceuticals policy / Food safety / Good manufacturing practice / Validation / Seminar / Medicine

supported by the EuBIS European Blood Inspection System Initiated under the Public Health Programme of the European Commission, DG Sanco, EC – GA No

DocID: 1rj7D - View Document

Health / Food and Drug Administration / Pharmaceuticals policy / Medicine / Food law / Dietary supplements / United States Public Health Service / Paul Offit / Good manufacturing practice / Federal Food /  Drug /  and Cosmetic Act / Adverse effect / Form FDA 483

Microsoft Word - MRI_Rebuttal_NYTimes_Article_1-7-14_Final.docx

DocID: 1r1ru - View Document